IV. Maligne Keimzellentumoren des Ovars (mOGCT)

REFERENZEN

Bafna U.D., Umadevi K., Kumaran C., Nagarathna D.S., Shashikala P., Tandem R.: Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int J Gynecol Cancer 2001 Jul–Aug; 11 (4): 300

Bianco B., Lipay M.V., Melaragno M.I., Guedes A.D., Verreschi I.T.: Detection of hidden Y mosaicism in Turner’s syndrome: importance in the prevention of gonadoblastoma. J Pediatr Endocrinol Metab 2006 Sep; 19 (9): 1113

Mangili G., Sigismondi C., Gadducci A., Cormio G., Scollo P., Tateo S., Ferrandina G., Greggi S., Candiani M., Lorusso D.: Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study. Int J Gynecol Cancer 2011 Nov; 21 (8): 1414

Murugaesu N., Schmid P., Dancey G., Agarwal R., Holden L., McNeish I. et al.: Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 2006; 24 (30): 4862

Vlasak I., Plöchl E., Kronberger G., Bergendi E., Rittinger O., Hagemann M., Schmitt K., Blümel P., Glatzl J., Fekete G., Kadrnka-Lovrencic M., Birkenstein M., Häusler G., Frisch H.: Screening of patients with Turner syndrome for „hidden“ Y-mosaicism. Klin Padiatr 1999; 211 (1): 30

Williams S.D., Kauderer J., Burnett A.F., Lentz S.S., Aghajanian C., Armstrong D.K.: Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol 2004 Dec; 95 (3): 496